Global Small Interfering RNA (siRNA) Therapeutics Market Size To Exceed USD 6.89 Billion By 2033 | CAGR of 14.37%
Category: HealthcareGlobal Small Interfering RNA (siRNA) Therapeutics Market Size To Exceed USD 6.89 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Global Small Interfering RNA (siRNA) Therapeutics Market Size is Expected to Grow from USD 1.8 Billion in 2023 to 6.89 Billion by 2033, at a CAGR of 14.37% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 245 pages with 110 Market data tables and figures & charts from the report on the "Global Small Interfering RNA (siRNA) Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Delivery (Lipid Nanoparticles (LNPs), Conjugates), By Indication (Hereditary Transthyretin-mediated Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Primary Hypercholesterolemia, Others), By RoA (Intravenous (IV), Subcutaneous), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/small-interfering-rna-sirna-therapeutics-market
Small interfering RNA (siRNA) treatments are a sort of medical intervention in which small, produced RNA molecules target disease-causing genes. The growing demand for precision medicine, new delivery systems, and improved molecular understanding of disease causes are driving market expansion for siRNA treatments. The global small interfering RNA (siRNA) therapeutics market presents significant opportunities, owing to the rising prevalence of genetic illnesses and the demand for precision medicine. The increased acceptability of personalized medicine, as well as potential growth in emerging economies, open up new avenues for siRNA applications, preparing this industry for substantial expansion. However, High development costs, regulatory restraints, and a lack of information about RNA-based medications all hamper market expansion. Maintaining stability while avoiding immunological reactions is a challenge that successful delivery techniques face.
The lipid nanoparticles (LNPs) segment is expected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market during the anticipation timeframe.
Based on delivery, the global small interfering RNA (siRNA) therapeutics market is categorized as lipid nanoparticles (LNPs), and conjugates. Among these, the lipid nanoparticles (LNPs) segment is expected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market during the anticipation timeframe. Growth is due to their superior ability to boost siRNA stability, protect against degradation, and improve targeted dispersion. LNPs allow excellent encapsulation, resulting in precise gene silencing and thereby enhancing their use in therapeutic applications.
The primary hyperoxaluria type 1 segment is expected to grow at the fastest CAGR during the anticipation timeframe.
Based on the indication, the global small interfering RNA (siRNA) therapeutics market is categorized as hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, primary hypercholesterolemia, and others. Among these, the primary hyperoxaluria type 1 segment is expected to grow at the fastest CAGR during the anticipation timeframe. This is due to the recent approval of lumasiran, a PH1-specific siRNA treatment, and also to increased awareness of the disease. Furthermore, the increased focus on treating rare genetic disorders, combined with expanded clinical trials and innovative treatment advancements, is driving significant market expansion in this area.
The subcutaneous segment is expected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market during the anticipation timeframe.
Based on RoA, the global small interfering RNA (siRNA) therapeutics market is categorized as intravenous (IV), and subcutaneous. Among these, the subcutaneous segment is expected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market during the anticipation timeframe. This is due to the convenience of self-administration, increased patient compliance, and reduced need for clinical visits. Subcutaneous distribution also enhances patient accessibility, and it has been widely employed in siRNA therapy for diseases such as hereditary transthyretin-mediated amyloidosis and primary hyperoxaluria type 1, contributing to its market dominance.
North America is projected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market over the anticipation timeframe.
Get more details on this report -
North America is projected to hold the largest share of the global Small Interfering RNA (siRNA) Therapeutics market over the anticipation timeframe. This growth is driven by major expenditures in biotechnology and pharmaceuticals, as well as a well-established healthcare infrastructure. The region contains strong academic and scientific resources, which foster innovation and clinical trials in siRNA treatments.
Europe is expected to grow at the fastest CAGR growth of the global small interfering RNA (siRNA) therapeutics market during the anticipation timeframe. The region benefits from a strong regulatory environment that promotes the discovery of new treatments, as well as an increased emphasis on personalized medicine. Increased R&D investments, as well as the increased prevalence of genetic disorders, are also driving market expansion.
Major vendors in the global small interfering RNA (siRNA) therapeutics market are Alnylam, Quark Pharmaceuticals, Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis, Novo Nordisk, Johnson & Johnson Company, GSK, Silence Therapeutics, Silenseed Ltd, Sylentis, S.A., Sanofi Genzyme, Aro Biotherapeutics, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Developments
- In May 2024, Wave Life Sciences demonstrated continued progress in their work with GSK, including substantial advancements in siRNA and RNA editing. Wave worked with GSK to establish its first two ideas for future development after successfully confirming their objectives. These applications utilized Wave's advanced GalNAc-siRNA format, which represents the next generation of hepatology technology.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global small interfering RNA (siRNA) therapeutics market based on the below-mentioned segments:
Global Small Interfering RNA (siRNA) Therapeutics Market, By Delivery
- Lipid Nanoparticles (LNPs)
- Conjugates
Global Small Interfering RNA (siRNA) Therapeutics Market, By Indication
- Hereditary Transthyretin-mediated Amyloidosis
- Acute Hepatic Porphyria
- Primary Hyperoxaluria Type 1
- Primary Hypercholesterolemia
- Others
Global Small Interfering RNA (siRNA) Therapeutics Market, By RoA
- Intravenous (IV)
- Subcutaneous
Global Small Interfering RNA (siRNA) Therapeutics Market, By Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?